Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 7, 2012, Pages 1116-1124

  Zhang, Hongyong ^a   Luo, Juntao ^b   Li, Yuanpei ^b   Henderson, Paul T ^a   Wang, Yanchun ^a   Wachsmann Hogiu, Sebastian ^a   Zhao, Weixin ^c   Lam, Kit S ^a,b   Pan, Chong xian ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Acute myeloid leukemia; C type lectin like molecule 1; Leukemia stem cells; Nanoparticles; Targeted therapy

Indexed keywords

13.5 NM; ACUTE MYELOID LEUKEMIA; C-TYPE LECTIN-LIKE MOLECULE-1; DAUNORUBICIN; DRUG LOAD; HEMATOPOIETIC STEM CELLS; HIGH-AFFINITY PEPTIDES; IN-VITRO; LEUKEMIC CELLS; MICELLAR NANOPARTICLES; NANOMICELLES; TARGETED DRUG DELIVERY; TARGETED THERAPY;

DRUG DELIVERY; FLOWCHARTING; MOLECULES; NANOPARTICLES; PEPTIDES; STEM CELLS;

DISEASES;

C TYPE LECTIN LIKE MOLECULE 1; CD34 ANTIGEN; CELL PROTEIN; DAUNORUBICIN; DENDRIMER; NANOCARRIER; NANOMICELLE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CELL ISOLATION; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEASIBILITY STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR TRANSPORT; LEUKEMIA STEM CELL; LIGAND BINDING; MATERIAL COATING; MICELLE; MOLECULARLY TARGETED THERAPY; PARTICLE SIZE; PROTEIN EXPRESSION; TARGET CELL;

AMINO ACID SEQUENCE; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LECTINS, C-TYPE; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; NANOPARTICLES; NEOPLASTIC STEM CELLS; PEPTIDES; PROTEIN BINDING;

EID: 84866522854     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.12.004     Document Type: Article

References (24)

1. Pan C.X., Zhu W., Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol 2006, 2:723-731.
2. Misaghian N., Ligresti G., Steelman L.S., Bertrand F.E., Basecke J., Libra M., et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009, 23:25-42.
3. Terpstra W., Ploemacher R.E., Prins A., van Lom K., Pouwels K., Wognum A.W., et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood 1996, 88:1944-1950.
4. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
5. Bakker A.B., van den Oudenrijn S., Bakker A.Q., Feller N., van Meijer M., Bia J.A., et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004, 64:8443-8450.
6. van Rhenen A., van Dongen G.A., Kelder A., Rombouts E.J., Feller N., Moshaver B., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110:2659-2666.
7. Zhao X., Singh S., Pardoux C., Zhao J., Hsi E.D., Abo A., et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 2010, 95:71-78.
8. Xiao K., Luo J., Fowler W.L., Li Y., Lee J.S., Xing L., et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 2009, 30:6006-6016.
9. Luo J., Xiao K., Li Y., Lee J.S., Shi L., Tan Y.H., et al. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem 2010, 21:1216-1224.
10. Lam K.S., Salmon S.E., Hersh E.M., Hruby V.J., Kazmierski W.M., Knapp R.J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991, 354:82-84.
11. Lam K.S., Lebl M., Krchnak V. The ' one-bead-one-compound' combinatorial library method. Chem Rev 1997, 97:411-448.
12. Zhang H., Aina O.H., Lam K.S., de Vere White R., Evans C., Henderson P., et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol 2010, 10.1016/j.urolonc.2010.06.011.
13. Chan W.C., White P.D. Fmoc solid phase peptide synthesis: a practical approach 2000, Oxford University Press, Oxford, UK.
14. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970, 34:595-598.
15. National Institutes of Health, National Cancer Institute High dose chemotherapy significantly prolongs survival for patients with acute myeloid leukemia. NCI News Center Available from, Accessed November 17 2008. http://www.cancer.gov/newscenter/pressreleases/2008/amldaunorubicin.
16. Fernandez H.F., Sun Z., Yao X., Litzow M.R., Luger S.M., Paietta E.M., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361:1249-1259.
17. Lowenberg B., Ossenkoppele G.J., van Putten W., Schouten H.C., Graux C., Ferrant A., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
18. Cortes J., Estey E., O'Brien S., Giles F., Shen Y., Koller C., et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001, 92:7-14.
19. Estey E.H. Therapeutic options for acute myelogenous leukemia. Cancer 2001, 92:1059-1073.
20. Feuring-Buske M., Frankel A.E., Alexander R.L., Gerhard B., Hogge D.E. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002, 62:1730-1736.
21. Hogge D.E., Yalcintepe L., Wong S.H., Gerhard B., Frankel A.E. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 2006, 12:1284-1291.
22. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
23. Zojer N., Kirchbacher K., Vesely M., Hubl W., Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006, 47:1103-1109.
24. Matsui W., Huff C.A., Wang Q., Malehorn M.T., Barber J., Tanhehco Y., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336.